Clyde Biosciences is a new spin-out company from the University of Glasgow which specialises in the design of award-winning platforms for the drug discovery process for large pharmaceutical companies.

Dr Margaret Anne Craig – biography

I graduated with a degree in Immunology/Pharmacology from the University of Strathclyde and went on to carry out a M.Sc. and Ph.D at the University of Glasgow in the field of pathophysiology of cancer. I then took up a position as research associate at the University of Glasgow where I was involved in the development of biological assays and novel discovery platforms as well as cardiovascular physiology research. I was awarded a BBSRC/RSE enterprise fellowship in 2011 which allowed me to spend one year validating our technologies, exploring the market potential and carrying out business training. During the course of the year, it became apparent that our technology had much commercial potential and we formed the spin-out company Clyde Biosciences. Last year I won the Royal Academy of Engineering National Entrepreneur of the Year for 2012. Subsequently, Clyde Biosciences has been shortlisted by the Times Higher Education awards for Outstanding Contribution to Technology and Innovation and by Scottish Enterprise as Innovators of the Year 2013. In my position as Chief Executive Officer, I will play a major role in shaping Clyde Biosciences into a world-leading CRO company.

Discussion points I could contribute to the committee include:

1) Sustaining a career in science as a female with children – issues arise due to short term contracts, lack of career structures and support to enable women back into the workplace.

2) Sustaining a high level career at boardroom level – careers at CEO level often require international travel and meetings and events in the evenings and early morning. How can we support women at this level who have difficulty maintaining these roles due to childcare restraints?

Dr Margaret Anne Craig
Royal Academy of Engineering UK Entrepreneur of the Year 2012
Chief Executive Officer
Clyde Biosciences
29 April 2013